<sentence id="0">Epigenetic modifications : new therapeutic targets in primary myelofibrosis .</sentence>
<sentence id="1">Primary Myelofibrosis previously also known as Agnogenic Myeloid Metaplasia or Idiopathic Myelofibrosis is a complex myeloproliferative disease .</sentence>
<sentence id="2">Although the initial genetic insult that causes uncontrolled proliferation of the defective Hematopoietic Stem Cell/Hematopoietic Progenitor Cell is still elusive , literature is being enriched with reports on the molecular mechanisms that provide growth advantage to the mutant clone and the secondary events that lead to stem cell mobilization , bone marrow fibrosis , osteosclerosis and angiogenesis .</sentence>
<sentence id="3">Identification of these mechanisms reveals dys-regulation of genes .</sentence>
<sentence id="4">Dys-regulation of genes that causes silencing of the tumor suppressors is of common occurrence in various cancers .</sentence>
<sentence id="5">Treatment methods have been targeted against the causative chromatin modifying agents such as DNA methyl transferases and Histone Deacetylases .</sentence>
<sentence id="6">Ensued success with inhibitors of these agents in the treatment of various cancers has gained precedent in the treatment of Primary Myelofibrosis .</sentence>
<sentence id="7">In vitro experiments with DNA methyl transferase inhibitors and HDAC inhibitors on patient samples provide promising results and clinical trials for the treatments of PMF patients are under way .</sentence>
<sentence id="8">Positive outcomes of such clinical trials could pave way for better treatment strategies for this complex disorder and improve the quality of life of these patients .</sentence>